低密度脂蛋白与收缩压联合降低的遗传变异与终生心血管疾病风险的相关性
该研究基于UK Biobank 2006至2010年入组、随访至2018年的438 952名参与者,用遗传LDL-C评分和SBP评分将人群分为终生低LDL-C、低SBP或两者联合暴露组,比较血浆LDL-C、SBP及心血管事件率差异。结果显示,两个遗传评分均高于中位数者LDL-C低13.9 mg/dL、SBP低3.1 mmHg,主要冠脉事件OR为0.61(95%CI 0.59-0.64,P<.001)。Meta回归分析中,LDL-C降低38.67 mg/dL联合SBP降低10 mmHg与主要冠脉事件OR 0.22(95%CI 0.17-0.26)及心血管死亡OR 0.32(95%CI 0.25-0.40)相关。作者结论认为终生遗传暴露于较低LDL-C和较低SBP与较低心血管风险相关,但这些发现不能假定代表治疗这些危险因素可达到的获益幅度。
要点
- 在438 952名UK Biobank参与者中,LDL-C遗传评分高于中位数者LDL-C低14.7 mg/dL,主要冠脉事件OR 0.73(95%CI 0.70-0.75,P<.001)。
- SBP遗传评分高于中位数者SBP低2.9 mmHg,主要冠脉事件OR 0.82(95%CI 0.79-0.85,P<.001)。
- 两个遗传评分均高于中位数者LDL-C低13.9 mg/dL、SBP低3.1 mmHg,主要冠脉事件OR 0.61(95%CI 0.59-0.64,P<.001)。
- Meta回归分析中,LDL-C降低38.67 mg/dL联合SBP降低10 mmHg与主要冠脉事件OR 0.22(95%CI 0.17-0.26,P<.001)及心血管死亡OR 0.32(95%CI 0.25-0.40,P<.001)相关。
- 作者结论指出,这些发现不能假定代表治疗这些危险因素可达到的获益幅度。
适用人群与场景
- UK Biobank于2006至2010年入组的438 952名参与者,平均年龄65.2岁(范围40.4-80.0岁),54.1%为女性,随访至2018年。
研究设计与关键结果
- 研究类型为UK Biobank队列的遗传评分分析,纳入438 952名参与者,随访至2018年,主要终点为主要冠脉事件(冠脉死亡、非致死性心肌梗死或冠脉血运重建),共24 980人发生首次主要冠脉事件。
- 与两个遗传评分均低于中位数的参照组相比,LDL-C遗传评分高于中位数者LDL-C低14.7 mg/dL,主要冠脉事件OR 0.73(95%CI 0.70-0.75,P<.001)。
- 与参照组相比,SBP遗传评分高于中位数者SBP低2.9 mmHg,主要冠脉事件OR 0.82(95%CI 0.79-0.85,P<.001)。
- 与参照组相比,两个遗传评分均高于中位数者LDL-C低13.9 mg/dL、SBP低3.1 mmHg,主要冠脉事件OR 0.61(95%CI 0.59-0.64,P<.001)。
- 4×4析因分析中,遗传风险评分升高及LDL-C和SBP降低与主要冠脉事件风险剂量依赖性降低相关。
- Meta回归分析中,LDL-C降低38.67 mg/dL联合SBP降低10 mmHg与主要冠脉事件OR 0.22(95%CI 0.17-0.26,P<.001)及心血管死亡OR 0.32(95%CI 0.25-0.40,P<.001)相关。
证据类型、等级与局限
- 证据类型为基于UK Biobank的队列遗传评分分析,原文未报告证据等级或推荐强度。
- 局限:作者结论指出这些发现不能假定代表治疗这些危险因素可达到的获益幅度。
对床旁实践的改变
- 作者认为,终生遗传暴露于较低LDL-C和较低SBP与较低心血管风险相关,但这些发现不能假定代表治疗这些危险因素可达到的获益幅度。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The relationship between exposure to lower low-density lipoprotein cholesterol (LDL-C) and lower systolic blood pressure (SBP) with the risk of cardiovascular disease has not been reliably quantified.
OBJECTIVE: To assess the association of lifetime exposure to the combination of both lower LDL-C and lower SBP with the lifetime risk of cardiovascular disease.
DESIGN, SETTING, AND PARTICIPANTS: Among 438 952 participants enrolled in the UK Biobank between 2006 and 2010 and followed up through 2018, genetic LDL-C and SBP scores were used as instruments to divide participants into groups with lifetime exposure to lower LDL-C, lower SBP, or both. Differences in plasma LDL-C, SBP, and cardiovascular event rates between the groups were compared to estimate associations with lifetime risk of cardiovascular disease.
EXPOSURES: Differences in plasma LDL-C and SBP compared with participants with both genetic scores below the median. Genetic risk scores higher than the median were associated with lower LDL-C and lower SBP.
MAIN OUTCOMES AND MEASURES: Odds ratio (OR) for major coronary events, defined as coronary death, nonfatal myocardial infarction, or coronary revascularization.
RESULTS: The mean age of the 438 952 participants was 65.2 years (range, 40.4-80.0 years), 54.1% were women, and 24 980 experienced a first major coronary event. Compared with the reference group, participants with LDL-C genetic scores higher than the median had 14.7-mg/dL lower LDL-C levels and an OR of 0.73 for major coronary events (95% CI, 0.70-0.75; P < .001). Participants with SBP genetic scores higher than the median had 2.9-mm Hg lower SBP and an OR of 0.82 for major coronary events (95% CI, 0.79-0.85, P < .001). Participants in the group with both genetic scores higher than the median had 13.9-mg/dL lower LDL-C, 3.1-mm Hg lower SBP, and an OR of 0.61 for major coronary events (95% CI, 0.59-0.64; P < .001). In a 4 × 4 factorial analysis, exposure to increasing genetic risk scores and lower LDL-C levels and SBP was associated with dose-dependent lower risks of major coronary events. In a meta-regression analysis, combined exposure to 38.67-mg/dL lower LDL-C and 10-mm Hg lower SBP was associated with an OR of 0.22 for major coronary events (95% CI, 0.17-0.26; P < .001), and 0.32 for cardiovascular death (95% CI, 0.25-0.40; P < .001).
CONCLUSIONS AND RELEVANCE: Lifelong genetic exposure to lower levels of low-density lipoprotein cholesterol and lower systolic blood pressure was associated with lower cardiovascular risk. However, these findings cannot be assumed to represent the magnitude of benefit achievable from treatment of these risk factors.
参考来源
- Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019. PMID: 31475726. doi:10.1001/jama.2019.14120
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。